Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Allena Pharmaceuticals (NASDAQ: ALNA) announced participation at the Stifel 2021 Virtual Healthcare Conference scheduled from November 15-17, 2021. Management will present on November 17 at 8:40 a.m. ET, focusing on the company's innovative oral biologic platform for treating difficult metabolic diseases. Their lead product, reloxaliase, is currently in a pivotal Phase 3 trial targeting enteric hyperoxaluria, a condition associated with elevated urinary oxalate levels impacting kidney health. Additional developments include ALLN-346 for hyperuricemia.

NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will present at the Stifel 2021 Virtual Healthcare Conference being held November 15^th-17^th 2021.

Please see the details for the presentation below:

Stifel 2021 Virtual Healthcare Conference
Date:	8:40 a.m. ET
Time:	Wednesday, November 17th, 2021
Webcast:	https://wsw.com/webcast/stifel58/alna/2067120

Management will also be available for 1x1 meetings. If you would like to request a meeting, please email stifelcorporateevents@stifel.com.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.

Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

FAQ

When is Allena Pharmaceuticals' presentation at the Stifel 2021 Virtual Healthcare Conference?

Allena Pharmaceuticals will present on November 17, 2021, at 8:40 a.m. ET.

What is the focus of Allena Pharmaceuticals' presentation at the conference?

The presentation will highlight Allena’s oral biologic platform for metabolic diseases, particularly their lead product, reloxaliase.

What is reloxaliase, the lead product of Allena Pharmaceuticals?

Reloxaliase is an oral enzyme therapeutic being evaluated for treating enteric hyperoxaluria, a metabolic disorder linked to kidney issues.

What other product is Allena Pharmaceuticals developing besides reloxaliase?

Allena is also developing ALLN-346 for treating hyperuricemia related to gout and chronic kidney disease.

How can interested parties request a meeting with Allena Pharmaceuticals during the conference?

Requests for one-on-one meetings can be made by emailing stifelcorporateevents@stifel.com.